Deutsche Bank
TCRR

Deutsche Bank’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Deutsche Bank’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,706
Closed -$57K – 4115
2022
Q2 		$57K Buy
19,706
+724
+4% +$1.79K ﹤0.01% 3718
2022
Q1 		$53K Buy
18,982
+461
+2% +$1.45K ﹤0.01% 3833
2021
Q4 		$86K Sell
18,521
-22,190
-55% -$139K ﹤0.01% 3769
2021
Q3 		$346K Buy
40,711
+21,101
+108% +$298K ﹤0.01% 3266
2021
Q2 		$322K Sell
19,610
-84,394
-81% -$1.7M ﹤0.01% 3504
2021
Q1 		$2.3M Buy
104,004
+295
+0.3% +$8.04K ﹤0.01% 2071
2020
Q4 		$3.21M Sell
103,709
-75,012
-42% -$1.9M ﹤0.01% 1612
2020
Q3 		$3.63M Buy
178,721
+170,823
+2,163% +$3M ﹤0.01% 1408
2020
Q2 		$121K Buy
7,898
+4,230
+115% +$48.8K ﹤0.01% 3357
2020
Q1 		$28K Sell
3,668
-234
-6% -$2.86K ﹤0.01% 3810
2019
Q4 		$55K Buy
3,902
+801
+26% +$12.4K ﹤0.01% 3930
2019
Q3 		$46K Buy
3,101
+1,761
+131% +$27.4K ﹤0.01% 3984
2019
Q2 		$18K Buy
+1,340
New +$21.4K ﹤0.01% 4842

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank's TCRR Position: Q3 2022 in Review

Deutsche Bank sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 19,706 shares — an estimated $57K sold.

Deutsche Bank first reported a position in TCRR in Q2 2019 and held it in 13 quarters. The position peaked at $3.63M in Q3 2020. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Deutsche Bank reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Deutsche Bank sold 19,706 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $57K.
  • Deutsche Bank first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • Deutsche Bank's TCR2 Therapeutics Inc. Common Stock position peaked at $3.63M in Q3 2020.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Deutsche Bank's 13F filing for Q3 2022, filed 14 Nov 2022.